Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

72.86 -7.62 (-9.47%)
Streaming Delayed Price Updated: 3:29 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗
Halozyme (HALO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗
Via Chartmill
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 51.6% year on year to $451.8 million. The... 
Via StockStory
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth at a Reasonable Price (GARP) Case ↗
Via Chartmill
News headline image
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
3 Small-Cap Stocks with Solid Fundamentals
In today’s market, large companies dominate the landscape and grow their leads by acquiring smaller competitors - a trend that will accelerate with the Trump administration. However, some lesser-known... 
Via StockStory
Topics Government
News headline image
3 Growth Stocks Set to Flourish
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition ↗
The biopharmaceutical company said that it now expects 2025 total revenue of $1.385 - $1.4 billion, representing a year-on-year growth of up to 38%. 
Via Stocktwits
News headline image
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Amgen (NASDAQ:AMGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
News headline image
Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Vertex Pharmaceuticals... 
Via StockStory
Topics Artificial Intelligence
News headline image
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty ↗
Could Halozyme Therapeutics be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing what investors need to know. 
Via The Motley Fool
News headline image
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Surging Stock Worth Investigating and 2 We Brush Off
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?
Halozyme Therapeutics has had an impressive run over the past six months as its shares have beaten the S&P 500 by 24.3%. The stock now trades at $75.77, marking a 35.8% gain. This was partly due to its... 
Via StockStory
Topics Stocks
News headline image
Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks
Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax (NASDAQ:NVAX) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.1% year on year to $354.3 million.... 
Via StockStory
News headline image
Halozyme Therapeutics (NASDAQ:HALO): A Prime GARP Stock with Strong Growth and Value ↗
Halozyme (HALO) exemplifies GARP investing, offering strong growth at a reasonable price with high profitability and a low P/E ratio. 
Via Chartmill
News headline image
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. ↗
Investing in Halozyme Therapeutics is a compelling way to gain exposure to the broader healthcare and biotechnology industries. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗
Halozyme (HALO) presents a strong value investment case with a low P/E ratio, high profitability, and solid growth, all at a discounted price. 
Via Chartmill
News headline image
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Bullish Technical Setup ↗
HALO stock shows strong EPS & revenue growth with a bullish technical setup, presenting a potential breakout opportunity for momentum investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.